ProCE Banner Activity

Strategies for Optimal HIV Treatment and Prevention: Considering Cabotegravir in Pregnancy

Multimedia
In this case example, learn about available data and recommendations for the use of long-acting cabotegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on long-acting cabotegravir and rilpivirine.

Released: September 28, 2022

Expiration: September 27, 2023

Share

Faculty

William R. Short

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS: non-CME/CE services: Janssen; consultant: ViiV Healthcare.

Staff Disclosure

Staff

Jessica L. Adams, PharmD, AAHIVE

Scientific Director, Infectious Diseases
Clinical Care Options
New York, United States

Jessica Adams, PharmD, BCPS, has no relevant financial relationships to disclose.

Geet Asnani,

Geet Asnani has no relevant financial relationships to disclose.

Ian Murphy, PhD

Ian Murphy, PhD, has no relevant financial relationships to disclose.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant financial relationships to disclose.